News
Eli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended for NHS use in England and Wales as a treatment for atopic dermatitis, also known as ...
After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...
AD is a growing market with an impressive pipeline of new products from current and future players in the field.
Eli Lilly LLY and partner Incyte INCY ... the phase III BRAVE-AA-PEDS study demonstrate Olumiant’s potential to address such needs. The drug was generally safe and overall well-tolerated in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback